Morita, Satoshi

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5,525

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 4,090

Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model

Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., et al. (2017) · Nature

Pluripotent Stem Cells ResearchParkinson's Disease Mechanisms and Treatments

Cited by 702

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2013) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 540

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 505

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis

Oba, K., Paoletti, X., Alberts, S., Bang, Y.-J., Benedetti, J., Bleiberg, H., Catalano, P., Lordick, F., Michiels, S., Morita, S., et al. (2013) · JNCI Journal of the National Cancer Institute

Gastric Cancer Management and OutcomesStatistical Methods in Clinical Trials

Cited by 168

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Urata, Y., Katakami, N., Morita, S., Kaji, R., Yoshioka, H., Seto, T., Satouchi, M., Iwamoto, Y., Kanehara, M., Fujimoto, D., et al. (2016) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 159

Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma

Honda, Y., Otsuka, A., Ono, S., Yamamoto, Y., Seidel, J. A., Morita, S., Hirata, M., Kataoka, T. R., Takenouchi, T., Fujii, K., et al. (2017) · OncoImmunology

Vascular Tumors and AngiosarcomasCancer Immunotherapy and Biomarkers

Cited by 72

Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026

Furuya, N., Fukuhara, T., Saito, H., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 59

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR ‐mutant non–small cell lung cancer: Multicenter, single‐arm, phase 2 trial (ABC Study)

Hata, A., Katakami, N., Kaji, R., Yokoyama, T., Kaneda, T., Tamiya, M., Inoue, T., Kimura, H., Yano, Y., Tamura, D., et al. (2018) · Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 42

Effects of telephone-delivered lifestyle support on the development of diabetes in participants at high risk of type 2 diabetes: J-DOIT1, a pragmatic cluster randomised trial

Sakane, N., Kotani, K., Takahashi, K., Sano, Y., Tsuzaki, K., Okazaki, K., Sato, J., Suzuki, S., Morita, S., Oshima, Y., et al. (2015) · BMJ Open

Diabetes Management and EducationMobile Health and mHealth Applications

Cited by 40

Clinical activity of ASP 8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Murakami, H., Nokihara, H., Hayashi, H., Seto, T., Park, K., Azuma, K., Tsai, C., Yang, J. C., Nishio, M., Kim, S., et al. (2018) · Cancer Science

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 17